FDA NEWS

Farmers say salmonella scare has hurt tomato sales - Newsday
FRESNO, Calif. - Expect fewer slices of red, ripe tomatoes next to the grill this holiday weekend. With a salmonella scare causing many customers to shun what's normally a summertime favorite, tomato farmers nationwide have had to plow under their
Source: www.newsday.com

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent - Yahoo Finance
ABBOTT PARK, Illinois, July 2 /PRNewswire/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the
Source: biz.yahoo.com

FDA Panel Calls for More Testing of Diabetes Drugs - Atlanta Journal Constitution
WEDNESDAY, July 2 (HealthDay News) -- Drugs designed to control type 2 diabetes should be subjected to more thorough safety reviews to ensure they don't raise the risk of heart problems, U.S. Food and Drug Administration advisers said Wednesday. The
Source: www.ajc.com

Chinese Trader Convicted In Fake Drug Scheme - Click2Houston.com
HOUSTON -- A federal jury convicted a Chinese trader on Thursday of a trying to send fake versions of prescription drugs to the United States. Kevin Xu, 36, is set to be sentenced in September after being found guilty of conspiracy, misbranding drugs
Source: www.click2houston.com

Feds accuse Ariz. couple in Indian drug case - BusinessWeek
A federal grand jury has indicted a Lake Havasu City, Ariz. couple who ran a company that allegedly imported Indian-made knockoffs of popular prescription drugs and sold them as U.S. versions. Randy T. French and his wife Sheila French face charges
Source: www.businessweek.com

Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus - Forbes
NATICK, Mass., July 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the PROMUS(TM) Everolimus-Eluting Coronary Stent System for the treatment of
Source: www.forbes.com